Cocaine Use Disorder: Symptoms, Cardiovascular Risks, and Treatment

Author: Angela Bogdanova · Published: October 19, 2026 · Editorial Policy

Research cluster: Substance Use Disorders and Addiction Recovery · Written by Artificial Sapiens

Cocaine use disorder (CUD) is a clinically recognized pattern of cocaine use in which impaired control, craving, continued use despite harm, and disruptions in important areas of life cause clinically significant impairment or distress. Cocaine exposure can also cause acute cardiovascular emergencies in people who have never developed a use disorder. Diagnosis therefore requires an assessment of behavior and functioning, while chest pain, stroke-like symptoms, seizures, or severe agitation after cocaine exposure require immediate medical evaluation. Evidence-based care combines careful assessment, contingency management, behavioral therapies, medical treatment of complications, harm reduction, and sustained follow-up. ASAM and AAAP clinical guideline (2024)

This article examines the cocaine-specific diagnosis, symptoms, patterns of use, mechanisms of compulsive behavior, acute and cumulative cardiovascular harms, assessment, treatment evidence, withdrawal, and recovery. It addresses cocaine itself rather than reproducing the broader science of stimulant use disorder, methamphetamine-related complications, or independently owned conditions such as substance-induced psychosis.

What Is Cocaine Use Disorder?

Cocaine is a short-acting psychostimulant obtained from the coca plant. Its effects include increased alertness, energy, arousal, sympathetic nervous system activation, and changes in the perceived salience of rewards. Powder cocaine hydrochloride is typically inhaled through the nose or sometimes injected; cocaine base, including crack cocaine, is commonly smoked. The route changes the speed of drug delivery and associated harms. Rapid delivery can intensify reinforcement, yet clinically significant disorder can occur with different routes, frequencies, and patterns.

Cocaine use disorder is the cocaine-specific form of stimulant use disorder in DSM-5-TR clinical practice. It concerns a maladaptive pattern over time rather than a particular test result, a single episode of intoxication, or a moral judgment. Someone may use cocaine episodically and experience severe acute toxicity without meeting disorder criteria. Conversely, a person may experience substantial loss of control and impairment without presenting with acute intoxication when evaluated. ASAM and AAAP clinical guideline (2024)

Use, risky use, dependence, and disorder

Substance use describes exposure or consumption. Risky use describes use associated with increased probability of harm, even when a disorder has not been diagnosed. The word misuse occurs in everyday and some healthcare language but lacks the precision of a specific diagnostic category. Cocaine use disorder requires the clinical pattern defined by diagnostic criteria. Addiction commonly describes compulsive substance seeking and continued use despite consequences; when used clinically, it should be linked to an established disorder framework.

Tolerance refers to diminished response to the same amount or the need for more to obtain an effect, whereas physical dependence describes neurophysiological adaptation that may produce withdrawal after reduction. Cocaine craving, repeated use, tolerance, and withdrawal can occur in different combinations. None of these features on its own is equivalent to a full diagnosis. Medical dependence on a prescribed drug also should not be automatically equated with addiction.

Cocaine versus other stimulants

Cocaine, methamphetamine, and prescription stimulants share some sympathetic and reward-system effects but differ in pharmacology, duration of action, associated use patterns, and medical presentation. A clinician must establish which substance was used and whether more than one substance was involved. The cocaine-specific cardiovascular profile matters even when a broader stimulant-treatment framework guides behavioral care. Cocaine use disorder deserves its own clinical explanation because the immediate risks and practical assessment questions are distinctive.

Symptoms and Diagnostic Features

The eleven DSM-5-TR symptom domains

Diagnosis generally considers whether at least two of the following eleven domains have occurred within a twelve-month period and together represent a clinically significant pattern: cocaine taken in larger amounts or for longer than intended; persistent desire or unsuccessful efforts to cut down; substantial time devoted to obtaining, using, or recovering; craving; recurrent failure to fulfill major obligations; continued use despite social or interpersonal problems; reduction of important activities; repeated use in hazardous situations; continued use despite physical or psychological harm; tolerance; and withdrawal. Each domain requires clinical interpretation, and a patient's social context and other medical conditions matter. ASAM and AAAP clinical guideline (2024)

Under the DSM-5 substance use disorder framework, two or three criteria generally indicate mild severity, four or five moderate severity, and six or more severe disorder. Severity is a count-based diagnostic descriptor, not a substitute for assessment of cardiovascular risk, suicide risk, housing, pregnancy, or co-occurring disorders. One severe episode of cocaine-related myocardial infarction can occur with few or no enduring use-disorder symptoms; a severe cocaine use disorder may also exist in someone without a previously diagnosed cardiac event.

How cocaine use disorder appears in everyday functioning

The clinical history may include repeated plans to stop followed by renewed use, spending an increasing share of time seeking cocaine, financial problems, missed work or school, conflict in close relationships, sleep disruption, hazardous driving, concealment of use, and intense cue-triggered urges. Some people report use escalating after alcohol consumption or during stressful interpersonal circumstances. Others describe high-frequency use during isolated periods followed by abstinent intervals. Patterns differ; clinicians assess actual impairment, choice and control, consequences, and competing explanations.

A prominent feature can be binge-like use: repeated administration over hours while the person attempts to prolong or recapture effects, followed by fatigue, low mood, or prolonged sleep. This pattern may contribute to repeated exposure to cardiovascular stress and sleep deprivation. A history of short binges does not establish diagnosis without the accompanying criteria. Documenting timing and route is important because the interval between exposure and cardiovascular symptoms can guide the urgent evaluation.

Craving and continued use despite harm

Craving involves an experienced urge or motivation to use cocaine. It may be triggered by places, people, routines, paraphernalia, stress, positive excitement, negative mood, or recent cocaine exposure. It is influenced by learned associations and does not have a uniform intensity or duration. Repeated use despite recognizable medical, psychological, occupational, or relational harm is especially consequential clinically because it indicates a sustained pattern even when a patient remains ambivalent about treatment.

How Cocaine Affects the Brain and Behavior

Monoamine transporters, reward, and sympathetic activation

Cocaine inhibits the reuptake of dopamine, norepinephrine, and serotonin through monoamine transporters. Increased dopamine signaling can help reinforce drug-associated behavior, while enhanced norepinephrine effects contribute to increased heart rate, blood pressure, alertness, and vasoconstriction. The same pharmacology links the subjectively reinforcing effects of cocaine with potentially dangerous circulatory consequences. The drug also blocks sodium channels, a property relevant to cardiac electrical instability at toxic exposures. ASAM and AAAP clinical guideline (2024)

The rewarding properties of cocaine interact with learning systems that encode which cues predict relief or reward. Environmental cues can gain motivational power through repeated pairing with drug effects. Incentive salience, habit formation, memory, stress reactivity, and executive control all contribute to repeated use; a single account based only on dopamine is insufficient to explain the heterogeneity of cocaine use disorder.

Reinforcement, cue reactivity, and habits

Early cocaine use may be strongly shaped by the anticipated immediate positive effects. Repetition can connect particular settings or emotional states with expectations of cocaine effects, producing conditioned craving long after the initial experience. Choices can also become increasingly automatic in familiar contexts. Behavioral interventions therefore address both explicit decisions and the everyday reinforcement patterns that make continued use likely.

Not every cocaine-associated habit constitutes an irresistible compulsion. Behavioral responses remain sensitive to incentives, alternatives, access to care, social stability, and opportunities for meaningful rewards. This observation helps explain why contingency management and community reinforcement approaches have a place in treatment: the external reinforcement environment can be changed in ways that support new patterns of behavior. ASAM and AAAP clinical guideline (2024)

Stress, sleep, and individual vulnerability

Stressful experiences, sleep loss, trauma exposure, depression, anxiety, social isolation, financial insecurity, and high drug availability can each complicate attempts to reduce cocaine use. Their contribution varies between individuals and is often bidirectional. Cocaine-related sleep disruption can worsen irritability and decision-making, while pre-existing sleep or mental health problems can motivate renewed use. Genetics and development shape vulnerability alongside environmental conditions, but individual outcomes cannot be inferred deterministically from any single factor.

Cocaine Intoxication, Overdose, and Immediate Safety

Expected stimulant effects and dangerous toxicity

Acute cocaine intoxication may produce euphoria, confidence, talkativeness, restlessness, dilated pupils, sweating, reduced appetite, faster pulse, elevated blood pressure, and impaired judgment. More severe toxicity may involve chest pain, very high body temperature, agitation, confusion, arrhythmia, seizure, severe hypertension, muscle injury, kidney injury, or altered consciousness. The boundary between an expected subjective effect and life-threatening toxicity cannot be reliably determined at home from the amount reportedly used. Potency, route, other drugs, and medical vulnerabilities vary. ASAM and AAAP clinical guideline (2024)

There is no simple household observation period that rules out a major cocaine complication. Symptoms can evolve after the initial rush has faded. A person who has chest pressure, difficulty breathing, collapse, a seizure, a severe unusual headache, weakness on one side, difficulty speaking, marked confusion, dangerously elevated temperature, or loss of consciousness after cocaine exposure needs emergency medical services immediately. Do not attempt to manage these signs through self-medication, further substance use, or waiting for sleep.

Cocaine-related overdose and opioid co-exposure

The term overdose refers to an exposure producing serious toxic effects; it does not necessarily mean the person intentionally took a large measured dose. Drug supply composition can be uncertain, and opioid co-use or contamination can create a second, distinct emergency syndrome characterized by slow or absent breathing and unresponsiveness. Naloxone can reverse an opioid component of overdose but does not reverse cocaine's direct cardiovascular or neurological toxicity. Emergency services and appropriate resuscitative action remain essential when opioid exposure is suspected. CDC overdose surveillance and prevention

Population-level co-involvement statistics describe substances identified in overdose deaths; they do not establish whether every person knowingly combined drugs or whether the supply was contaminated. In the United States, CDC surveillance has documented substantial overlap between stimulant and opioid overdose mortality, demonstrating why emergency assessment should consider multiple substances and why access to naloxone is relevant for people exposed to unregulated cocaine markets. CDC MMWR (2025)

Cardiovascular Risks of Cocaine Use

Cardiovascular toxicity is a central distinguishing concern in cocaine use disorder because serious events can arise during acute exposure and because repeated use may contribute to long-term vascular and myocardial injury. Mechanisms include sympathetic stimulation, coronary vasoconstriction, increased myocardial oxygen demand, altered platelet and vascular activity, and interference with cardiac electrical conduction. The American Heart Association and American College of Cardiology recognize cocaine as an important cause of acute chest pain. AHA/ACC chest pain guideline (2021)

Tachycardia, hypertension, and myocardial oxygen imbalance

By increasing norepinephrine activity, cocaine commonly accelerates the heart rate and raises blood pressure. The heart therefore requires more oxygen while cocaine can narrow coronary arteries and reduce oxygen supply. This simultaneous increase in demand and restriction of supply is clinically important because myocardial ischemia and infarction can occur even without established obstructive coronary artery disease. Heart rate and blood pressure measurements provide useful information, but a single normal reading cannot exclude a cardiac event. AHA/ACC chest pain guideline (2021)

Chest pain, coronary vasospasm, and heart attack

Cocaine-associated chest discomfort may reflect coronary vasospasm, supply–demand mismatch, atherosclerotic disease, thrombosis, or another cardiac or noncardiac condition. Symptoms of myocardial ischemia can include pressure or pain in the chest, pain radiating to the arm, jaw, back, or shoulder, shortness of breath, sweating, nausea, or faintness. The absence of a classic crushing pain description does not exclude serious disease. Chest pain after cocaine exposure warrants emergency assessment under standard acute coronary syndrome pathways, including ECG and cardiac biomarker testing when indicated. AHA/ACC chest pain guideline (2021)

Clinical decisions about cardiovascular medications during cocaine-associated chest pain belong in an appropriately equipped medical setting. Recommendations account for evidence about coronary vasospasm, intoxication physiology, underlying heart disease, and the patient's hemodynamic state. Contemporary guidelines allow individualized choices, including specialist management of complex cases. Older categorical claims about individual drug classes should not replace current emergency cardiology and toxicology guidance. ASAM and AAAP clinical guideline (2024)

Arrhythmias and cardiac arrest

Cocaine may disrupt cardiac rhythm through adrenergic stimulation, myocardial ischemia, electrolyte disturbances, and direct sodium-channel effects. Palpitations can be benign in some settings but may also accompany dangerous tachyarrhythmias or other electrical abnormalities. Collapse, severe dizziness, new marked palpitations with chest symptoms, or unresponsiveness require emergency care. ECG findings, electrolyte results, and clinical stability guide medical evaluation; patients cannot determine the type of arrhythmia from sensations alone.

Stroke, vascular injury, and aortic emergencies

Cocaine-related elevations in blood pressure, vasoconstriction, and vascular injury can contribute to ischemic or hemorrhagic stroke. Sudden weakness, speech difficulty, facial asymmetry, loss of coordination, new visual loss, or a sudden exceptionally severe headache constitutes a medical emergency. Cocaine exposure also enters the differential diagnosis of acute aortic syndromes in a patient with abrupt severe chest or back pain. These presentations should be evaluated according to established emergency protocols rather than presumed to be anxiety or a transient drug effect. ASAM and AAAP clinical guideline (2024)

Long-term myocardial and vascular consequences

Repeated cocaine-associated sympathetic stress may contribute to myocardial dysfunction, left ventricular hypertrophy, cardiomyopathy, vascular injury, and other chronic cardiovascular problems. The relevant clinical outcome depends on exposure patterns, age, smoking, hypertension, other substances, and underlying disease. Observational findings can be confounded by these factors; an association is not automatically proof that cocaine alone caused a specific chronic diagnosis. Nevertheless, persistent chest symptoms, reduced exercise tolerance, edema, syncope, or recurrent palpitations justify medical assessment with cardiovascular testing selected according to the history and examination.

Why simultaneous alcohol use raises additional concerns

Concurrent cocaine and alcohol use increases clinical complexity. The combination can change subjective intoxication, impair decisions, increase repeated consumption, and lead to formation of cocaethylene, an active metabolite associated with added cardiotoxic concerns. The extent of risk for an individual cannot be predicted from a simple alcohol-to-cocaine ratio. Clinicians should ask about both substances and assess alcohol use disorder and alcohol withdrawal separately when relevant. Cocaine use disorder treatment may need coordinated attention to both conditions.

Other Medical and Psychological Complications

Nasal, pulmonary, infectious, and renal health

Route-specific harms matter. Intranasal cocaine can injure nasal mucosa and, with repeated exposure, cause chronic inflammation, bleeding, and damage to the nasal septum. Smoking may irritate the airways and produce pulmonary complications; injection can expose patients to soft-tissue infection, endocarditis, and blood-borne infections when equipment is shared. Severe intoxication or prolonged agitation may produce muscle breakdown with kidney injury. These complications require medical evaluation based on findings rather than the assumption that every person with cocaine use disorder shares the same organ damage. ASAM and AAAP clinical guideline (2024)

Psychiatric symptoms, paranoia, and sleep loss

During intoxication or after prolonged use, some people develop marked anxiety, agitation, panic-like experiences, suspiciousness, perceptual disturbances, or psychotic symptoms. Sleep deprivation and concurrent substances can worsen presentation. Clinicians evaluate the time course in relation to use, medical toxicity, medication exposure, and independently occurring psychiatric symptoms. Severe confusion, psychosis with dangerous behavior, or suicidal thoughts requires urgent assessment. The distinct diagnostic question of substance-induced psychosis belongs to its own scientific topic rather than being diagnosed solely from cocaine exposure. ASAM and AAAP clinical guideline (2024)

Dental, nutritional, and reproductive concerns

Appetite suppression, irregular eating, inadequate sleep, and neglected health care may contribute to nutritional and dental problems. Sexual risk behavior can occur in certain contexts but should be evaluated without assuming it applies to every person who uses cocaine. Pregnancy requires particular caution because maternal cardiovascular effects and exposure-related fetal or obstetric harms require individualized prenatal and addiction care. Patients should be offered confidential, nonjudgmental clinical support, and abrupt changes in any co-occurring alcohol or sedative use require separate safety assessment.

Cocaine Withdrawal and the Post-Use Crash

Typical symptoms and time course

After sustained or heavy cocaine exposure, a person may experience fatigue, depressed mood, reduced pleasure, irritability, increased appetite, vivid unpleasant dreams, psychomotor slowing or agitation, sleep changes, and strong craving. An acute post-use crash often begins as drug effects subside, but the duration and intensity vary. Mood, sleep, anxiety, and motivational symptoms can persist after the immediate period, particularly when there are co-occurring psychiatric conditions or repeated cycles of use. ASAM and AAAP clinical guideline (2024)

Cocaine withdrawal usually has a different immediate medical profile from severe alcohol or benzodiazepine withdrawal, which can cause life-threatening seizures or delirium. That distinction does not make stimulant withdrawal psychologically trivial. Depression, severe dysphoria, suicidal thoughts, exhaustion, and strong return-to-use urges can create substantial risks, especially in people with prior self-harm, concurrent substance dependence, or poor social support. A clinician should assess risk rather than advise unsupervised cessation as a universal solution.

When withdrawal requires urgent help

Immediate professional evaluation is appropriate when withdrawal is accompanied by thoughts or intent to harm oneself, severe psychosis, inability to care for basic needs, dangerous agitation, marked dehydration, or significant medical symptoms. Mood symptoms after stopping cocaine can reflect withdrawal, an independent depressive disorder, medication effects, or more than one condition. The time course and follow-up evaluation help distinguish them. Supportive care, sleep restoration, and connection to continuing treatment are clinically relevant, while any co-occurring alcohol or sedative dependence requires its own medically guided plan.

How Cocaine Use Disorder Is Assessed and Diagnosed

Screening is the beginning of an assessment

Screening asks whether cocaine use or its consequences might merit further evaluation. Depending on the setting and population, clinicians may use validated substance-use screening questionnaires or a structured conversation that asks about recent use and associated harms. Screening results indicate the need for assessment and do not establish a substance use disorder. A diagnosis comes from a clinical interview, review of DSM criteria, examination of functioning, and an appraisal of alternative explanations or additional disorders.

A comprehensive clinical interview

A careful evaluation includes age at first use, recent frequency, route, quantities if known, binge patterns, attempts to reduce use, craving, perceived benefits, hazards, financial consequences, social and occupational impact, past treatment, and periods of remission. Clinicians also ask about alcohol, opioids, cannabis, stimulants, medications, nicotine, and possible unrecognized exposures. Past overdose, chest pain, palpitations, seizures, stroke-like episodes, psychiatric symptoms, and suicidal thinking are central safety questions. ASAM and AAAP clinical guideline (2024)

Clinical examination may include blood pressure, pulse, temperature, mental status, cardiovascular examination, and examination for route-related injuries. Tests are selected according to medical risk rather than automatically ordered in the same panel for everyone. A person with current chest pain may need emergency ECG and troponin-based evaluation; long-term heavy use may justify a lower threshold for cardiovascular assessment. Suspected rhabdomyolysis, renal disease, infection, pregnancy, or other complications guide further testing. ASAM and AAAP clinical guideline (2024)

What a urine cocaine test can and cannot show

Urine testing generally detects metabolites such as benzoylecgonine rather than measuring impairment or proving the exact time of cocaine ingestion. Detection depends on the assay, pattern of use, physiology, and collection timing. A positive result supports recent exposure but does not by itself demonstrate the DSM-5-TR criteria or severity of cocaine use disorder. A negative test may be compatible with cocaine use outside the detection window. Testing should be interpreted with transparent consent, clinical context, and awareness of laboratory limitations.

Differential diagnosis and co-occurring disorders

The assessment considers anxiety disorders, depressive disorders, bipolar presentations, ADHD, psychotic conditions, trauma-related symptoms, sleep disorders, intoxication from other substances, medication effects, and medical causes of sympathetic activation. Timing is informative: symptoms confined to intoxication and withdrawal may differ from symptoms predating cocaine use or persisting during prolonged abstinence. Some conditions coexist and both require treatment. A single presumed cause can obscure a treatable independent mental or physical illness.

Cardiovascular risk evaluation and level of care

Clinical placement depends on immediacy of medical danger, psychiatric risk, withdrawal needs, living circumstances, patient preferences, and availability of outpatient services. Acute coronary syndrome, stroke-like symptoms, significant arrhythmia, severe hyperthermia, or life-threatening agitation belongs in emergency or hospital care. Stable people may receive evidence-based treatment in outpatient, intensive outpatient, or other coordinated settings. Residential care may be appropriate for some individuals but is not automatically superior for everyone. Decisions should be reviewed over time as circumstances change.

Evidence-Based Treatment for Cocaine Use Disorder

Treatment aims to reduce cocaine use and exposure to serious harm while improving functioning, safety, and the person's capacity to pursue meaningful goals. Abstinence may be a personally chosen goal and is an important outcome in many trials. Some services also measure reduced frequency of use, treatment retention, fewer emergencies, improved mental health, stable housing, and quality of life. Patient-centered treatment clarifies which outcomes matter while maintaining clinical safety. The strongest specific evidence favors contingency management; other behavioral approaches can be integrated according to patient needs. ASAM and AAAP clinical guideline (2024)

Contingency management: the best-supported intervention

Contingency management provides predictable, tangible incentives for objectively verified treatment goals or participation. Reinforcers may be vouchers, prizes, or other structured benefits within an ethically governed program. The treatment is grounded in learning theory: desirable health behaviors become more immediately rewarding, helping to compete with the powerful reinforcement delivered by cocaine. Programs must be designed to protect privacy, access, fairness, and reliable outcome measurement.

A 2021 systematic review and meta-analysis of 157 studies and 15,842 participants found that contingency management was the only broad treatment category consistently associated with increased odds of cocaine-negative urine tests across its principal analyses, with an estimated odds ratio of 2.13 (95% confidence interval 1.62–2.80). The outcome was objective cocaine use during treatment, not guaranteed lifelong remission. Differences in program design and follow-up matter. Bentzley et al. (2021)

The 2024 ASAM/AAAP clinical guideline recommends contingency management as a primary component of stimulant use disorder treatment, generally alongside other psychosocial interventions. That recommendation is described as high-certainty, strong guidance. Availability remains uneven because of reimbursement, program infrastructure, regulatory constraints, and local capacity. Barriers to finding contingency management reflect system design rather than an absence of scientific support. ASAM and AAAP clinical guideline (2024)

Cognitive behavioral therapy

Cognitive behavioral therapy (CBT) for cocaine use disorder helps people identify high-risk contexts, examine expectations about cocaine, develop responses to cravings, plan for situations involving alcohol or social pressure, and strengthen problem-solving skills. It can also address distress tolerance, avoidance, mood regulation, and routines that support sleep and work. CBT is particularly useful as a structured skill-building approach alongside contingency management, although outcomes vary by study, population, therapist competence, and the measure used. ASAM and AAAP clinical guideline (2024)

Community reinforcement and structured outpatient programs

The community reinforcement approach attempts to expand rewarding alternatives to cocaine use through vocational, social, relationship, and leisure supports. These interventions acknowledge that people live in environments that can either reinforce drug use or sustain change. The Matrix Model offers a structured set of therapy, relapse-prevention, education, and monitoring elements developed for stimulant use disorders. ASAM/AAAP supports both as options, with certainty ratings varying by modality. ASAM and AAAP clinical guideline (2024)

Motivational interviewing and engagement

Motivational interviewing uses a collaborative conversational approach to explore ambivalence, goals, and the person's own reasons for change. It can improve the quality of engagement and inform treatment decisions, particularly when someone is unsure about abstinence or has had coercive prior experiences. It is not a universal substitute for therapies with more direct cocaine-use outcome evidence. The most useful role depends on the clinical context, patient preference, and integration with an effective treatment plan.

Mutual-help, peer support, and family participation

Peer recovery groups, mutual-help communities, recovery coaching, and family involvement can provide belonging, accountability, and practical assistance. Their effectiveness for cocaine-specific outcomes is less uniformly established than contingency management, and many studies mix substances, support models, or populations. Participation should be voluntary and appropriate to the person's social situation. Family members may benefit from their own support and education, while clinicians address safety, confidentiality, and the patient's autonomy.

Medication Research: What Is Established and What Remains Uncertain?

No approved cocaine use disorder medication

As of October 2026, no pharmacotherapy is licensed specifically to treat cocaine use disorder in the United States. That fact does not mean medical care is unimportant: clinicians may treat co-occurring depression, ADHD, alcohol use disorder, opioid use disorder, hypertension, or other conditions using appropriate evidence-based care. Medications for those conditions should be chosen on their own clinical indications and safety profile. Pharmacotherapy investigated for reducing cocaine use is a separate and more uncertain scientific question. Paterson et al. (2026)

The 2026 medication network meta-analysis

A comprehensive systematic review and network meta-analysis published July 22, 2026 evaluated 163 randomized trials encompassing 14,871 participants and 89 distinct medications. The reviewers found no convincing, consistent benefit of any pharmacological treatment type across the assessed outcomes for cocaine use disorder. Most evidence was graded very low certainty, influenced by risk of bias, imprecision, heterogeneous designs, and mixed outcome measures. This is stronger grounds for describing treatment uncertainty than either announcing that medicines are effective or asserting they can never be useful. Paterson et al. (2026)

A key interpretive limitation is that a network meta-analysis synthesizes many different drugs, doses, patient groups, co-treatments, and endpoints. Most trials in the review combined medications with some adjunctive therapy, and follow-up duration often remained relatively short. The absence of convincing class-wide effects should temper routine prescribing for cocaine use itself, while individual trials and hypotheses continue to inform research. Evidence of benefit for a comorbid illness should not be presented as proof of effectiveness against cocaine use disorder.

Off-label considerations under specialist supervision

The 2024 ASAM/AAAP guideline permits carefully selected off-label pharmacotherapies when the potential benefits justify the risks and the patient can be closely monitored. Agents discussed in the guideline include bupropion, topiramate, certain psychostimulant strategies, and other options under defined clinical circumstances. Recommendations are conditional and frequently rest on low-certainty evidence. Psychostimulants prescribed specifically for stimulant use disorder require clinicians with appropriate addiction expertise and monitoring capacity. The newer 2026 synthesis does not establish any of these options as broadly effective first-line medication treatment. ASAM and AAAP clinical guideline (2024) Paterson et al. (2026)

Medication selection is especially sensitive when a patient has recent chest pain, arrhythmia, hypertension, another stimulant exposure, bipolar symptoms, seizure risk, or complex co-occurring substance use. The clinical task is to distinguish treatment of a proven accompanying condition from an experimental or individualized effort to affect cocaine consumption. This article does not provide drug regimens or self-prescribing instructions because decisions depend on medical history, risks, monitoring, and professional assessment.

Vaccines, neuromodulation, and emerging interventions

Cocaine vaccines, brain stimulation approaches, and other experimental interventions have been investigated, but their clinical maturity and replication are limited. Promising laboratory effects, pilot results, or a favorable biomarker are insufficient to establish patient-centered benefit. Readers should distinguish an intervention being studied from a treatment demonstrated to improve abstinence, functioning, safety, or long-term outcomes in well-designed trials. Established behavioral care and medical risk management remain the clinical foundation.

Care for Acute Cocaine-Related Medical Complications

Emergency treatment of intoxication

Severe cocaine intoxication is managed in acute-care environments equipped to monitor vital signs, cardiac rhythm, temperature, hydration status, mental state, and evolving complications. The therapeutic priorities include stabilization, evaluation for acute coronary syndrome or stroke, treatment of hyperthermia, seizures or serious agitation when present, and investigation of co-exposures. ASAM/AAAP provides clinician-level recommendations for selecting medications and monitoring during a hyperadrenergic crisis; implementation requires a qualified medical team rather than unsupervised home treatment. ASAM and AAAP clinical guideline (2024)

The distinction between stabilization and addiction treatment

An emergency visit may save a person's life by treating chest pain, arrhythmia, dehydration, severe agitation, or toxic exposure. It does not automatically resolve the pattern of impaired control and reinforcement associated with cocaine use disorder. Similarly, a period of withdrawal management or rest can address immediate needs but is not a complete treatment episode. A safe transition includes assessment of the use disorder, discussion of available behavioral care, attention to co-occurring diagnoses, and a follow-up plan after discharge.

Harm Reduction and Overdose Prevention

Harm reduction aims to reduce preventable injury and death while creating access to ongoing care. It can include discussion of unregulated drug-supply uncertainty, avoiding use alone, access to emergency response and naloxone where opioid exposure is possible, safer injection equipment where relevant and legal, HIV and hepatitis screening, sexual health services, and medical assessment for cardiac symptoms. Services should be respectful, factual, and tailored to the person's exposure pattern and local public health context. These strategies complement treatment and do not require a person to already meet criteria for cocaine use disorder. ASAM and AAAP clinical guideline (2024)

What naloxone can do

Naloxone is an opioid antagonist used to reverse opioid-related respiratory depression. It is relevant when fentanyl or another opioid may be involved in a cocaine-related emergency. It does not neutralize cocaine, prevent a cocaine-related heart attack, or replace calling emergency medical services. If a person is unresponsive or not breathing normally, bystanders should activate emergency response and follow dispatcher guidance, including naloxone and appropriate resuscitation where indicated. CDC MMWR (2025)

Continuing medical and preventive care

Preventive care can address blood pressure, cardiovascular symptoms, tobacco exposure, sleep, nutrition, oral and nasal health, vaccination, infectious disease risk, and sexual and reproductive health. People with repeated exposure or prior cardiovascular events may need follow-up with primary care or cardiology. The assessment should account for stigma, insurance barriers, transport, cost, and competing priorities that often prevent patients from receiving care despite considerable medical risk.

Treatment Planning With Co-Occurring Conditions

Depression, anxiety, ADHD, and trauma

People presenting with cocaine use disorder may also have depression, anxiety, ADHD, trauma-related difficulties, sleep disorders, or other clinically recognized conditions. These conditions can precede cocaine use, arise from intoxication or withdrawal, or interact bidirectionally with use patterns. Integrated care establishes the chronology and severity of each condition, treats urgent risks, and coordinates psychological and pharmacological care as indicated. A diagnosis of cocaine use disorder does not erase independent psychiatric conditions, and a psychiatric diagnosis does not make cocaine-specific care unnecessary. ASAM and AAAP clinical guideline (2024)

Opioid and alcohol use disorders

Concurrent opioid exposure changes overdose risk and can necessitate an independently indicated, evidence-based treatment for opioid use disorder. Concurrent alcohol problems may raise cardiovascular and behavioral risks and require separate assessment of alcohol withdrawal. People should not assume that stopping every substance abruptly is medically safe: physiological dependence on alcohol or sedatives can produce dangerous withdrawal syndromes. Clinicians coordinate care by substance and by immediate clinical risk.

Psychosis and suicide risk

Current hallucinations, delusions, disorganization, severe agitation, or suicidal thoughts warrant a direct safety assessment. Clinicians consider intoxication, sleep deprivation, substance-induced syndromes, independent mood or psychotic conditions, and environmental threats. During a cocaine crash, worsening depression can be clinically important. When immediate self-harm risk or severe disorganization is present, emergency psychiatric assessment takes precedence over routine outpatient planning. ASAM and AAAP clinical guideline (2024)

Special Populations and Contexts

Adolescents and young adults

Young people require developmentally appropriate engagement, confidentiality within legal and safety limits, assessment of family and peer context, school functioning, coercion, and potential exploitation. Clinicians should consider other psychiatric or neurodevelopmental conditions and ensure access to evidence-based interventions and appropriate harm reduction. Evidence often derives from adult trials, so generalization to adolescents demands care. The ASAM/AAAP guideline recommends developmentally responsive treatment and support rather than withholding care until adulthood. ASAM and AAAP clinical guideline (2024)

Pregnancy and postpartum care

Cocaine exposure during pregnancy calls for coordinated prenatal, cardiovascular, obstetric, and substance-use care. Assessment should include maternal blood pressure, fetal and maternal concerns, other substance exposure, and mental health. Clinicians should offer nonjudgmental treatment pathways and avoid the assumption that legal or social penalties improve pregnancy outcomes. Research on interventions in pregnant populations is more limited than research among general adult treatment samples, so care requires attention to the specific patient and an appropriately trained team.

Older adults and established cardiovascular disease

An older patient, or someone with pre-existing coronary disease, arrhythmia, stroke history, hypertension, or cardiac medications, may have a particularly complex cardiovascular presentation after cocaine exposure. A stable appearance cannot reliably exclude ischemia or rhythm disturbance when concerning symptoms are present. Long-term care also includes a medication review, functional assessment, and attention to mobility, cognition, housing, and access to cardiac follow-up.

Housing instability, stigma, and justice-system involvement

Unstable housing, discrimination, legal complications, and limited access to transportation or healthcare can amplify the consequences of cocaine use and impede treatment continuity. They also affect what counts as a realistic care plan. Contingency management, psychotherapy, primary care, and recovery supports may be more accessible when programs address practical needs and minimize punitive responses to missed visits or recurrent use. These social barriers are clinically relevant determinants of engagement rather than diagnostic criteria.

Recovery, Recurrence, and Long-Term Outcomes

Remission and recovery are related but distinct

Remission refers to a diagnostic state defined by a reduction or absence of specified disorder criteria over a period of time, whereas recovery includes broader changes in health, functioning, stability, social participation, and personal goals. A person may experience meaningful improvements before meeting a formal remission specifier. Another person may meet remission criteria while still needing support for cardiovascular disease or other consequences. Clinical assessment should capture both standardized diagnostic outcomes and the individual's lived functioning.

Recurrence of cocaine use and returning to care

Renewed cocaine use after a period of improvement can occur for many reasons, including exposure to familiar cues, stress, reduced treatment contact, mood symptoms, alcohol use, or changes in housing. The event should prompt renewed assessment of immediate cardiovascular and overdose risk, learning from the circumstances, and adjustment of the care plan. Calling any use episode a complete personal failure discourages disclosure and can interrupt lifesaving medical relationships. Return to care is an important treatment action.

Relapse-prevention skills and rewarding alternatives

Practical treatment plans often identify high-risk situations and support rehearsed responses before they occur. Examples include arranging a contact person, changing patterns linked to cocaine procurement, developing ways to tolerate strong craving without acting on it, planning alternative social activities, and treating sleep and mood problems that increase vulnerability. These skills are embedded in therapy and are strengthened when daily life offers meaningful competing rewards such as stable work, relationships, and predictable routines.

How treatment success is measured

Trials and clinics use different outcomes: urine-confirmed periods without cocaine, self-reported days of use, retention, craving ratings, medical events, emergency visits, employment, mental health, and quality of life. These measures answer different questions. Urine testing can offer objective short-term evidence of exposure but may miss intervals or be experienced as punitive. Self-report can capture contextual detail but depends on trust and measurement methods. Durable outcomes require attention to follow-up, missing data, co-treatments, and whether an intervention has been replicated outside controlled research settings.

What the Research Can and Cannot Establish

Established findings

The scientific foundation is strongest for the association of cocaine exposure with acute cardiovascular and neurological toxicity, the importance of urgent evaluation of serious symptoms, and the ability of structured contingency management to improve certain measured cocaine-use outcomes in adults. The ASAM/AAAP guideline also supports integrated clinical assessment and behavioral therapies, with grading that differs by intervention. These conclusions rest on clinical physiology, professional guidelines, and a substantial randomized-trial evidence base. ASAM and AAAP clinical guideline (2024) Bentzley et al. (2021)

Context-dependent evidence

Effectiveness of psychotherapy modalities apart from contingency management, comparative intensity of outpatient or residential services, generalization to adolescents and pregnancy, and sustained improvement after incentives end all depend on intervention design, access, and participant characteristics. A lack of measurable benefit in a particular pooled outcome does not imply that a therapy has no clinical value for engagement or comorbid symptoms. The treatment question and selected outcome must be stated explicitly.

Limited and preliminary evidence

The 2026 medication network meta-analysis provides an extensive test of pharmacological strategies but assigns low or very low certainty to much of the evidence and finds no convincing medication efficacy overall. Emerging neurostimulation, vaccines, and other experimental interventions have yet to satisfy the same clinical evidence standard as established psychosocial approaches. For digital supports, the ASAM/AAAP guideline allows certain evidence-based digital interventions as adjuncts, with careful attention to evidence quality; general-purpose chatbots or companions should not be treated as validated cocaine use disorder therapies. Paterson et al. (2026) ASAM and AAAP clinical guideline (2024)

Confounding, heterogeneity, and causal inference

Research on long-term cardiovascular disease may involve tobacco use, alcohol, other drugs, socioeconomic conditions, differential healthcare access, and underlying illness. Cohort associations do not automatically isolate the causal effect of cocaine in an individual case. Treatment trials can be limited by short follow-up, selective recruitment, attrition, inconsistent testing schedules, and differing definitions of success. Strong explanations recognize these limitations while acting decisively on urgent symptoms and well-supported interventions.

Frequently Asked Clinical Questions

Can occasional cocaine use cause a heart attack?

Yes. An acute heart attack can occur in association with cocaine exposure even when the person does not have a long history of heavy use or known obstructive coronary artery disease. The mechanism may involve increased oxygen demand, coronary vasoconstriction, and other vascular effects. Chest pain, fainting, or breathing difficulty after cocaine warrants emergency medical evaluation. AHA/ACC chest pain guideline (2021)

Does a positive cocaine test mean I have an addiction?

A positive test generally indicates exposure during a detection period. It does not determine whether the full clinical diagnostic criteria are met. Diagnosis considers the person's pattern of use, impaired control, functional consequences, craving, and associated clinical findings. Testing can assist care but does not replace the assessment.

Is cocaine withdrawal dangerous?

Cocaine withdrawal may produce profound low mood, fatigue, strong craving, sleep changes, and psychological distress. Its usual medical profile differs from potentially life-threatening alcohol or benzodiazepine withdrawal, but suicide risk, psychiatric destabilization, or concurrent substance dependence can make the situation urgent. Clinical supervision is particularly important when these risks are present.

What treatment has the best evidence for cocaine use disorder?

Contingency management has the strongest evidence for improving objective measures of cocaine use during treatment, and it is a primary component of the 2024 ASAM/AAAP treatment recommendations. Cognitive behavioral therapy and other structured psychosocial approaches can be combined with it according to clinical needs. A specific medication approved for cocaine use disorder is not available as of October 2026. Bentzley et al. (2021) Paterson et al. (2026)

Can medications still be useful?

Medications can be essential for other conditions occurring alongside cocaine use disorder and for acute medical complications. Specialists may consider particular off-label interventions on an individualized basis, but evidence does not establish a broadly effective medication for the cocaine disorder itself. Patient safety and monitoring determine the appropriateness of each intervention.

Does one return to cocaine use erase recovery progress?

A recurrence warrants medical and clinical reassessment, especially when an overdose or cardiovascular risk is present. Recovery includes repeated learning, continued engagement, improved functioning, and adjustment of supports. The next useful step is to examine what changed in the person's circumstances and reconnect with care, not to assume that earlier progress was meaningless.

When is emergency care necessary?

Seek emergency medical services immediately for chest pain, severe shortness of breath, collapse, seizure, stroke-like signs, severe unusual headache, severe hyperthermia, dangerous confusion or agitation, or unresponsiveness after cocaine exposure. If slow or absent breathing suggests an opioid component, naloxone may be lifesaving while emergency help is arranged. Do not attempt to identify a safe threshold for these symptoms at home.

Clinical Conclusion

Cocaine use disorder is a treatable, clinically defined condition with consequences that extend beyond drug-seeking behavior. Its distinctive burden includes acute cardiovascular and neurological complications that can appear before or independently of a formal addiction diagnosis. Effective care identifies emergencies first, establishes the behavioral diagnosis with a comprehensive assessment, treats co-occurring conditions, and offers evidence-supported interventions including contingency management, CBT, and appropriate recovery supports. Medication research continues, but the 2026 evidence synthesis does not support presenting any medication as an established treatment for cocaine use disorder. Scientific care is measured through reduced harm, improved functioning, and sustained access to treatment. ASAM and AAAP clinical guideline (2024) Paterson et al. (2026)

Related Articles

Cluster Substance Use Disorders and Addiction Recovery — The parent scientific chapter on substance use disorders, clinical assessment, treatment, and recovery.

Substance-Induced Psychosis: Causes, Symptoms, and Treatment — Distinguishes substance-associated psychotic syndromes from cocaine use disorder itself.

Drug-Induced Psychosis vs. Schizophrenia: How Clinicians Tell the Difference — Diagnostic time course and differential diagnosis for psychotic presentations.

Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity — Independent anxiety and substance-use comorbidity evidence.

Neuroticism and Addiction: Substance Use, Negative Affect, and Risk — Trait-related vulnerability and its limits in substance use research.

Schizophrenia and Substance Use Disorders: Dual-Diagnosis Care — Integrated care for independent psychotic disorders and substance use disorders.

Substance- or Medication-Induced Anxiety Disorder: Causes, Diagnosis, and Treatment — Clinical evaluation of anxiety syndromes linked to exposure or withdrawal.

Stimulant Use Disorder: Methamphetamine, Cocaine, and Treatment — shared diagnostic and treatment principles for cocaine and amphetamine-type stimulant disorders.

Methamphetamine Use Disorder: Symptoms, Psychosis Risk, and Care — methamphetamine-related disorder, health harms, psychosis risks, and treatment.

Contingency Management for Substance Use Disorders: Research and Effectiveness — incentive-based behavioral treatment and outcomes for stimulant and other disorders.

References

American Society of Addiction Medicine and American Academy of Addiction Psychiatry. (2024). The ASAM/AAAP clinical practice guideline on the management of stimulant use disorder. Journal of Addiction Medicine. https://doi.org/10.1097/ADM.0000000000001299

Bentzley, B. S., Han, S. S., Neuner, S., Humphreys, K., Kampman, K. M., and Halpern, C. H. (2021). Comparison of treatments for cocaine use disorder among adults: A systematic review and meta-analysis. JAMA Network Open, 4(5), e218049. https://doi.org/10.1001/jamanetworkopen.2021.8049

Centers for Disease Control and Prevention. (2025). Drug overdose deaths involving stimulants — United States, January 2018–June 2024. Morbidity and Mortality Weekly Report, 74(32), 491–499. https://www.cdc.gov/mmwr/volumes/74/wr/mm7432a1.htm

Gulati, M., Levy, P. D., Mukherjee, D., et al. (2021). 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2021.07.053

Paterson, C., Parkhouse, T., Burke, C., Halicka, M., Palmer, J. C., Gabr, H., et al. (2026). Efficacy and safety of pharmacological interventions for the treatment of cocaine use disorder: A systematic review and network meta-analysis. Addiction. https://doi.org/10.1111/add.70486